Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Carcinoma, Squamous Cell
  • Hemoptysis
  • Lung Neoplasms

abstract

  • In a cohort of patients with resected lung cancers at high risk of hemoptysis, including those with SQCLC, treatment with adjuvant bevacizumab did not result in hemoptysis of any grade.

publication date

  • August 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4653739

Digital Object Identifier (DOI)

  • 10.1007/s00280-013-2219-5

PubMed ID

  • 23811982

Additional Document Info

start page

  • 453

end page

  • 61

volume

  • 72

number

  • 2